The Immunology and Cancer (IC) Program has been an integral part of the UCCCC for more than 25 years. It has 22 members from 6 Departments, and is supported by a total of $13,081,506 in annual peer reviewed funding (direct costs), of which $2,351,962 comes from the NCI. Over the previous funding period (encompassing 4 years). Program members have produced a total of 219 peer-reviewed cancer relevant publications, with 29% published in the highest impact journals;18% of these were interprogrammatic and 9% were intraprogrammatic. The broad goals of the Immunology and Cancer Program are to understand the interface between the host immune system and a malignant tumor and, ultimately, to manipulate that interaction to promote immune-mediated tumor destruction in patients with cancer. It is well established that tumors can express antigens that can be recognized by specific T cells or antibodies. Identifying the reasons why a given cancer is not eliminated spontaneously should highlight the major barriers that need to be overcome in order to restore immune control over the tumor. The research themes of the program focus on understanding the mechanisms of innate immune activation and productive antigen presentation;activation and differentiation of lymphocytes into effector/memory states;trafficking into inflamed target tissues and control of local inflammation;and overcoming mechanisms of peripheral immune tolerance. Basic concepts are integrated into mouse preclinical tumor models, and novel clinical trials are performed to capitalize on this new knowledge translationally, many in collaboration with clinical investigators outside of the Program. The clinical/translational effort is supported by several key Core Facilities, in particular the Human Immunologic Monitoring-cGMP Facility. By incorporating detailed scientific endpoint monitoring into clinical studies, new key information is generated that has led to the development of new hypothesess that are interrogated back in the laboratory. Thus, the Immunology and Cancer Program is a clear example of bi-directional translational research.

Public Health Relevance

A deeper understanding of the regulation of the host immune response against tumors has led to new immunotherapy approaches for the treatment of cancer. The recent FDA approval of ipilimumab for melanoma has generated a paradigm shift for the field. Furthering our basic knowledge in this arena and continuing the development of novel immunotherapies should translate into more durable clinical outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-39
Application #
8744828
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
39
Fiscal Year
2014
Total Cost
$15,782
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Liu, Hongtao; Zha, Yuanyuan; Choudhury, Noura et al. (2018) WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Exp Hematol Oncol 7:1
Nageeb, Shaheen; Vu, Milkie; Malik, Sana et al. (2018) Adapting a religious health fatalism measure for use in Muslim populations. PLoS One 13:e0206898
Ferreira, Caroline M; Williams, Jesse W; Tong, Jiankun et al. (2018) Allergen Exposure in Lymphopenic Fas-Deficient Mice Results in Persistent Eosinophilia Due to Defects in Resolution of Inflammation. Front Immunol 9:2395
Luke, Jason J; Lemons, Jeffrey M; Karrison, Theodore G et al. (2018) Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 36:1611-1618
Wang, Amy Y; Weiner, Howard; Green, Margaret et al. (2018) A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol 11:4
Sample, Ashley; He, Yu-Ying (2018) Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 34:13-24
Jeong, Choongwon; Witonsky, David B; Basnyat, Buddha et al. (2018) Detecting past and ongoing natural selection among ethnically Tibetan women at high altitude in Nepal. PLoS Genet 14:e1007650
Wang, Xin; Wu, Xingye; Zhang, Zhonglin et al. (2018) Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 8:17914
Brown, Hailey M; Biering, Scott B; Zhu, Allen et al. (2018) Demarcation of Viral Shelters Results in Destruction by Membranolytic GTPases: Antiviral Function of Autophagy Proteins and Interferon-Inducible GTPases. Bioessays 40:e1700231
Karrison, Theodore; Kocherginsky, Masha (2018) Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials 15:178-188

Showing the most recent 10 out of 668 publications